Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

Phase 1TerminatedNCT03509545

Sarfez Pharmaceuticals, Inc.20 enrolled

Overview

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Body Weight Changes

Interventions

CHF Patients: ER Torsemide 40 mgDRUG

ER Torsemide 40mg given once daily to CHF patients

CHF Patients: Furosemide 40 mgDRUG

Stable CHF patients taking twice-daily 40 mg Furosemide

Eligibility

Sex: MALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide. Exclusion Criteria: * Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.

Locations (1)

Syngene International

Bangalore, Karnataka, India

Outcomes

Primary Outcomes

change in 24-hour sodium excretion compared to baseline

the difference in 24 hour sodium excretion between ER Torsemide and Furosemide

Time frame: 24 hours

Secondary Outcomes

Changes in body weight

Body weight changes will be compared between the two arms

Time frame: 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.